Exelixis
EXEL
#1775
Rank
โ‚น812.21 B
Marketcap
โ‚น2,844
Share price
0.86%
Change (1 day)
56.31%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): โ‚น50.05 Billion

According to Exelixis's latest financial reports the company's current earnings are โ‚น2.08 Billion. In 2023 the company made an earning of โ‚น22.27 Billion, an increase over its 2022 earnings that were of โ‚น20.27 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) โ‚น50.05 B124.71%
2023 โ‚น22.27 B9.89%
2022 โ‚น20.27 B-20.33%
2021 โ‚น25.44 B124.82%
2020 โ‚น11.31 B-67.14%
2019 โ‚น34.43 B-11.94%
2018 โ‚น39.10 B185.09%
2017 โ‚น13.71 B-325.82%
2016 -โ‚น6.08 Billion-58.12%
2015 -โ‚น14.51 Billion-37.61%
2014 -โ‚น23.25 Billion9.75%
2013 -โ‚น21.18 Billion65.96%
2012 -โ‚น12.77 Billion-291.63%
2011 โ‚น6.65 B-195.59%
2010 -โ‚น6.97 Billion-42.17%
2009 -โ‚น12.05 Billion-18.98%
2008 -โ‚น14.88 Billion-6.99%
2007 -โ‚น15.99 Billion46.3%
2006 -โ‚น10.93 Billion33.25%
2005 -โ‚น8.21 Billion-30.92%
2004 -โ‚น11.88 Billion44.29%
2003 -โ‚น8.23 Billion12.86%
2002 -โ‚น7.3 Billion22.79%
2001 -โ‚น5.94 Billion60.14%
2000 -โ‚น3.71 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
โ‚น360.77 B 595.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น640.77 B 1,134.83%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น1.295 T 2,395.89%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น595.12 Billion-1,246.85%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น404.72 B 679.96%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.591 T 2,966.31%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น600.56 B 1,057.35%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น3.88 Billion-107.47%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น2.52 Billion-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA